Proteomic profiling is another approach used to discover new biomarkers of sensitivity to targeted therapy in NSCLC: This approach has revealed novel phosphorylation sites of EGFR Y1197 and other proteins such as MAPK7 and DAP1 (14); however, this has not yet resulted in change of clinical practice. This evidence concerns the gene EGFR and non-small cell lung carcinoma.